- €941.31m
- €913.90m
- €19.52m
Brief: Teva & Medincell Announce FDA Approval Of Uzedy (Risperidone) Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults
Brief: Medincell Announces Initiation Of Phase 3 Study For Injectable Antipsychotic
Brief: MedinCell H1 Net Financial Loss At 2.1 Million Euros
Brief: Medincell: Additional $4 Mln Received For 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive
Brief: EIB And Medincell Sign New €40 Million Loan Agreement
Brief: Medincell's Partner Teva Today Announced Refiling For Approval Of Mdc-Irm And Confirmed Planned Launch In U.S. In H1 2023
Brief: MedinCell Signs Licence Deal With Medicines Patent Pool For Malaria
Brief: Medincell Secures Additional EUR 20 Mln Financing With European Investment Bank
Brief: MedinCell: Clinical Phase 3 Trial For mdc‑TJK To Be Initiated
French and Benelux stocks-Factors to watch
Brief: Medincell FY Net Loss Widens To EUR 24.8 Mln
Brief: Medincell Pharma Names Richard Malamut As Chief Medical Officer
Brief: Mithra CDMO Announces Collaboration With MedinCell For Development Of Injectable Products For Malaria And Transplant Rejection
Teva Pharmaceuticals slide after FDA rejects schizophrenia treatment
Brief: MedinCell Announces Inclusion Of First Participants In New Covid-19 Prophylaxis Clinical Trial SAIVE
Brief: Medincell H1 Operating Loss Widens To EUR 11.2 Mln
Brief: Medincell Receives EUR 4 Mln In Funding From Bpifrance
Brief: Medincell: Phase 3 Data Of mdc-IRM Shows Significant Improvements In Patients With Schizophrenia
Brief: Teva And MedinCell Announce FDA Acceptance Of New Drug Application For TV-46000/mdc-IRM As A Treatment For Patients With Schizophrenia